BiovaxID^®: a customized idiotype vaccine for the treatment of B-cell lymphoma

References

• Swerdlow SH, Campo E, Harris NL et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition). IARC Press, Lyon, France (2008).
   Google Scholar
• Bendandi M. Aiming at a curative strategy for follicular lymphoma. CA Cancer J. Clin.58(5), 305–317 (2008).
   PubMed Web of Science ®Google Scholar
• Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit. Rev. Oncol. Hematol.80(1), 69–86 (2011).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures. Nat. Rev. Cancer9(9), 675–681 (2009).
   PubMed Web of Science ®Google Scholar
• Inogés S, de Cerio AL, Soria E, Villanueva H, Pastor F, Bendandi M. Idiotype vaccines for human B-cell malignancies. Curr. Pharm. Des.16(3), 300–307 (2010).
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol.29(20), 2787–2794 (2011).
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Kwak LW, Kobrin CB et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med.11(9), 986–991 (2005).
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood117(19), 5019–5032 (2011).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia14(8), 1333–1339 (2000).
   PubMed Web of Science ®Google Scholar
• de Cerio AL, Zabalegui N, Rodríguez-Calvillo M, Inogés S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene26(25), 3594–3602 (2007).
   PubMed Web of Science ®Google Scholar
• Carroll WL, Thielemans K, Dilley J, Levy R. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods89(1), 61–72 (1986).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Zabalegui N, Villanueva H, Bendandi M. Variations in “rescuability” of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development. Crit. Rev. Oncol. Hematol.52(1), 1–7 (2004).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Tonelli R, Maffei R et al. Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers. Ann. Oncol.12(10), 1479–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Inogés S, de Cerio AL, Zabalegui N et al. Prolonged idiotipic vaccination against follicular lymphoma. Leuk. Lymphoma50(1), 47–53 (2009).
   PubMed Web of Science ®Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med.327(17), 1209–1215 (1992).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med.5(10), 1171–1177 (1999).
   PubMed Web of Science ®Google Scholar
• Barrios Y, Cabrera R, Yáñez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica87(4), 400–407 (2002).
   PubMed Web of Science ®Google Scholar
• Inogès S, Rodrìguez-Calvillo M, Zabalegui N et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl Cancer Inst.98(18), 1292–1301 (2006).
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood89(9), 3129–3135 (1997).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol.22(23), 4717–4724 (2004).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Rodríguez-Calvillo M, Inogés S et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk. Lymphoma47(1), 29–37 (2006).
   PubMed Web of Science ®Google Scholar
• Longo DL. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl Cancer Inst.98(18), 1263–1265 (2006).
   PubMed Web of Science ®Google Scholar
• Ansell SM, Suman VJ. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine. J. Clin. Oncol.29(20), 2748–2749 (2011).
   PubMed Web of Science ®Google Scholar
• Longo DL, DeVita VT Jr, Duffey PL et al. Superiority of ProMACE-CytaBOM over ProMACEMOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J. Clin. Oncol.9(1), 25–38 (1991).
   PubMed Web of Science ®Google Scholar
• Longo DL, Duffey PL, Gribben JG et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a Phase 2 study. Cancer J.6(3), 146–150 (2000).
   PubMed Web of Science ®Google Scholar
• Bendandi M, Marillonnet S, Kandzia R et al. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin’s lymphoma. Ann. Oncol.21(12), 2420–2427 (2010).
   PubMed Web of Science ®Google Scholar
• Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood109(3), 951–953 (2007).
   PubMed Web of Science ®Google Scholar
• Levy R, Robertson M, Leonard J et al. Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared with non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non Hodgkin’s lymphoma (FNHL). Ann. Oncol.19(Suppl. 4), iv101–iv102 (2008).
   Google Scholar
• Freedman A, Neelapu SS, Nichols C et al. Placebo-controlled Phase 3 trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J. Clin. Oncol.27(18), 3036–3043 (2009).
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104(5), 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Bendandi M. Clinical benefit of idiotype vaccines: too many trials for a clever demonstration? Rev. Recent Clin. Trials1(1), 67–74 (2006).
   PubMedGoogle Scholar
• Hagenbeek A. Monoclonal antibodies (update): CD20, rituximab. Hematol. Meeting Rep.2, 50–51 (2008).
   Google Scholar
• Inogés S, de Cerio AL, Villanueva H, Soria E, Pastor F, Bendandi M. Idiotype vaccines for lymphoma therapy. Expert Rev. Vaccines10(6), 801–809 (2011).
   PubMed Web of Science ®Google Scholar
• Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood99(7), 2562–2568 (2002).
   PubMed Web of Science ®Google Scholar
• Zabalegui N, de Cerio AL, Inogés S et al. Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies. Haematologica89(5), 541–546 (2004).
   PubMed Web of Science ®Google Scholar
• Radcliffe CM, Arnold JN, Suter DM et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J. Biol. Chem.282(10), 7405–7415 (2007).
   PubMed Web of Science ®Google Scholar
• McCann KJ, Ottensmeier CH, Callard A et al. Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. Mol. Immunol.45(6), 1567–1572 (2008).
   PubMed Web of Science ®Google Scholar
• Coelho V, Krysov S, Ghaemmaghami AM et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc. Natl Acad. Sci. USA107(43), 18587–18592 (2010).
   PubMed Web of Science ®Google Scholar
• Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract. Res. Clin. Haematol.24(2), 147–163 (2011).
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Alencar AJ et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood118(5), 1350–1358 (2011).
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Rosenwald A, Poppema S, Lenz G. Prognostic biomarkers in malignant lymphomas. Leuk. Lymphoma51(Suppl. 1), 11–19 (2010).
   PubMed Web of Science ®Google Scholar